Ascendis down 7% after R&D update

Ascendis Pharma A/S (ASND -6.8%) is down on almost triple normal volume as its R&D Day event in New York winds down with a Q&A session.

Developing…

Update: Shares are down 10% approaching the close as investors appear to be reacting to additional data from the fliGHT and heiGHT studies comparing TransCon hGH to Genotropin.

Slide presentation

https://seekingalpha.com/news/3474010-ascendis-7-percent-r-and-d-update